

Haematologica
HAEMATOL/2017/174672
Version 4

Treatment of essential thrombocythemia in Europe: a prospective long-term observational study of 3649 high-risk patients in the EXELS study

Gunnar Birgegard, Carlos Besses, Martin Griesshammer, Luigi Gugliotta, Claire N. Harrison, Mohamed Hamdani, Jackie Wu, Henri Achenbach, and Jean-Jacques Kiladjian

Disclosures: CH received honoraria for speaking and advisory board membership from Shire, Novartis, Sanofi, Gilead, YM Biosciences, S Bioscience, and CTI BioPharma, and research funding from Novartis. GB received funding for consultancy and honoraria from Shire, and Uppsala University received research funding from Shire. J-JK received honoraria from Shire and Novartis, and is a member of an advisory committee for Shire and Novartis. JW is an employee of Shire. LG received honoraria and reimbursement for attending symposia, from Shire. MG received honoraria from Shire, Novartis, Sanofi, Amgen, and Roche. MH is an employee of Shire and owns Shire stocks and shares.

Contributions: The authors would like to thank the contribution of all investigators who participated in this study (Appendix I). Under the direction of the authors, Donna Tillotson, PhD, employee of iMed Comms, an Ashfield Company, provided writing assistance for this publication. Editorial assistance in formatting, proofreading, copy editing, and fact checking was also provided by iMed Comms. Shire Pharmaceutical Development Ltd provided funding to iMed Comms for support in writing and editing this manuscript. The study was funded by the Sponsor, Shire Pharmaceutical Development Ltd. The study was designed by the international EXELS steering committee (GB, J-JK, CB, MG, LG, CH), chaired by GB, who is also the lead and corresponding author, and developed the final draft of the manuscript. CB, MG, LG, CH, J-JK all enrolled patients to the study, analyzed the data and critically reviewed the manuscript. HA contributed to the study management, interpretation of the data and critically reviewed the manuscript. MH and JW undertook the statistical and multivariate analysis and critically reviewed the manuscript for data accuracy. All authors provided final approval of the manuscript, and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Although the Sponsor was involved in the design, collection, analysis, interpretation, and fact checking of information, the content of this manuscript, the ultimate interpretation, and the decision to submit it for publication in Haematologica was made by the authors independently.